Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Hepion Pharmaceuticals, Inc. (CTRV) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Pre-Funded Warrant",
"Form of Series A Warrant",
"Form of Series B Warrant",
"Sheppard, Mullin, Richter & Hampton LLP Legal Opinion",
"Form of Securities Purchase Agreement",
"Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules EDISON, N.J., September 29, 2023 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis , fibrotic diseases, hepatocellular carcinoma , and other chronic diseases, today announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of 980,393 shares of its common stock at a purchase price of $5.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement,..."
07/24/2023 8-K Quarterly results
07/21/2023 8-K Quarterly results
05/10/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "CERTIFICATE OF AMENDMENT",
"Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split EDISON, NJ, / May 10, 2023 / Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis , hepatocellular carcinoma , and other chronic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time today, May 10, 2023. Hepion common stock will begin trading on a split-adjusted basis when the market opens on May 11, 2023 under the existing trading symbol “HEPA.” As a result of the reverse stock split, the CUSIP number for the Company’ s common stock will now be 42689..."
12/15/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/08/2022 8-K Quarterly results
10/17/2022 8-K Investor presentation
Docs: "Hepion Pharmaceuticals, Inc. Corporate Presentation"
08/05/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
01/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Hepion Pharmaceuticals Announces Death of Director, Thomas Adams"
01/10/2022 8-K Investor presentation
Docs: "Hepion Pharmaceuticals, Inc. Corporate Presentation"
01/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431 EDISON, N.J., January 6, 2022 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and other liver diseases, today announced the United States Adopted Names Council has adopted the nonproprietary name “rencofilstat” for the Company’ s lead drug candidate, CRV431. The USAN Council works closely with the International Nonproprietary Name Programme of the World Health Organization and various national nomenclature groups to achieve global standardization and unification of drug nomenclature and related rules with the goal of ensuring that drug informa..."
12/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer"
11/30/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH EDISON, N.J., November 30, 2021 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and other liver diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company’ s lead drug candidate, CRV431, for the treatment of NASH. The FDA Fast Track designation allows sponsors to gain access to expedited drug approval reviews for medical conditions that are serious and potentially life-threatening, and where there is an unmet medical need. The program is also designed to facilitate drug development by ma..."
11/16/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study EDISON, N.J., November 16, 2021 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and other liver diseases, today announced the results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. Additionally, CRV431 was as effective at decreasing tumor burden as an anti-PD1 antibody immune checkpoint inhibitor, PD1 antibody, and produced more beneficial changes in tumor infiltrating cells compared to anti-PD1 antibody treatment. The study was conducted by ..."
11/10/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 EDISON, N.J., November 10, 2021 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and other liver diseases, today announced that results from its Phase 2a ‘AMBITION’ NASH trial will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases , to be held virtually November 12-15, 2021. Poster Details",
"Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 EDISON, N.J., November 10, 2021 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and other liver diseases, today announced that results from a study conducted by Dr. Philippe Gallay’ s research group at The Scripps Research Institute examing the anti-tumor mechanism of the Company’ s lead drug candidate, CRV431, will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases , to be held virtually November 12-15, 2021. Poster Details · ..."
10/08/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
10/07/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference EDISON, N.J., October 7, 2021 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, today announced that its CMO, Dr. Todd Hobbs, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021, at 4:00 p.m. Eastern Time. The virtual presentation will be broadcast live and archived on the Company's website at www.hepionpharma.com under "Events" in the “Investors” section. The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes...."
09/30/2021 8-K Investor presentation
Docs: "Hepion Pharmaceuticals, Inc. Corporate Presentation"
09/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431 EDISON, N.J., September 29, 2021 - Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, today announced results from a Drug-Drug Interaction study with its lead drug candidate, CRV431. CRV431 targets several isoforms of cyclophilins which comprise a family of enzymes involved in processes including collagen production, inflammation, cell injury, cell death, and protein folding. Attenuation of the activities of this multifunctional enzyme family represents a novel approach to the treatment of NASH. The randomized, open label DDI study was conducte..."
09/13/2021 8-K Quarterly results
08/23/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to Bylaws of Hepion Pharmaceuticals, Inc"
07/23/2021 8-K Quarterly results
07/13/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Forward Looking Statements"
06/25/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy